BridgeBio Pharma Inc (NAS:BBIO)
$ 27.94 0.18 (0.65%) Market Cap: 5.23 Bil Enterprise Value: 6.44 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 48/100

BridgeBio Pharma Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript

Jun 11, 2020 / 02:30PM GMT
Release Date Price: $27.79 (-4.80%)
Paul Choi
Goldman Sachs Group, Inc., Research Division - Equity Analyst

Okay. We will continue with the next session, which is BridgeBio Pharma. Good morning, everyone. I'm Paul Choi, the SMid cap biotechnology analyst here at Goldman Sachs. And it's my great pleasure to introduce the founder and CEO of BridgeBio, Neil Kumar, who will walk us through some opening comments on the BridgeBio story. After that, we'll go into Q&A. And as in previous sessions, if investors or clients have comments or questions for the management, in this case Neil, please feel free to submit them through the Goldman Sachs research portal. And time permitting at the end, we'll try and squeeze in a question or 2. Alternatively, you can submit questions to me directly, and I'll read them at the end, as I mentioned.

And with that, I'll turn it over to Neil for some opening comments and then we'll go into Q&A.

Neil Kumar
BridgeBio Pharma, Inc. - Co-Founder, President, CEO & Director

Great. Thanks, Paul. Really appreciate the opportunity to present and field

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot